Drugs / AQ001S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05000346 | Nov 2021 → Dec 2022 | COVID-19 | Aquilon Pharmaceuticals S.A. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AQ001S | “AQ001S 0.125 mg/mL inhalation solution administered by inhalation 4 times a day” NCT05000346 ↗ |
| Route | Inhaled | “administered by inhalation” NCT05000346 ↗ |